Articles

Unleashed seeking to harness new markets

Data management company Unleashed Informatics recently introduced its Unleashed Global Services arm to complement its bioinformatics software and hardware offerings.
Written byLisa Espenschade
| 2 min read

TORONTO—Data manage­ment company Unleashed Informatics recently intro­duced its Unleashed Global Services arm to complement its bioinformatics software and hardware offerings.

Unleashed added the ser­vices after noticing how visi­tors used its portal to explore online products. "What we observed," says Eric Andrade, Unleashed's president and CEO, "was they start out with one product or service that they know and then they begin to explore the notion of integration. It's integra­tion of publicly available sources that is intriguing to them, being able to combine genomics with proteomics."

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue